Operational Excellence

SHERIDAN, WYOMING - December 8, 2025 - Teleste is sharpening its execution muscle in the fast-growing public safety and mobility market by appointing project delivery specialist Jaakko Keski-Nisula as Head of Project Management for its Public Safety and Mobility business unit, a new leadership role designed to boost delivery performance on complex, safety-critical infrastructure projects.

New leadership role targets large, complex public transport projects

Based in Turku, Finland, Keski-Nisula will join the business unit's Leadership Team and report to Senior Vice President Public Safety and Mobility, Valerian Sand. His remit: strengthen Teleste's project management capabilities across international deployments in public transport and security, where customers increasingly expect turnkey, integrated solutions with predictable timelines and service levels.

SHERIDAN, WYOMING - December 8, 2025 - After a year of mixed signals from U.S. regulators, rare disease executives and policy experts are urging the FDA to match its pro-innovation rhetoric with clearer, more consistent rules for approvals, arguing that uncertainty around evidence standards is starting to chill investment and slow the next wave of therapies.

Mixed Messages from an Activist, Rare-Disease-Friendly FDA

Under Commissioner Marty Makary and CBER director Vinay Prasad, the FDA has made high-profile statements in favor of easing market access for rare disease treatments and even floated a "plausible mechanism" pathway for ultrarare conditions. Yet in practice, sponsor experience has been uneven.

SHERIDAN, WYOMING - December 8, 2025 - The CDC's Advisory Committee on Immunization Practices (ACIP) has triggered a major shift in U.S. newborn immunization policy, voting 8-3 to delay the hepatitis B vaccine for infants born to hepatitis B-negative mothers from the traditional birth dose to two months of age, despite decades of evidence and CDC messaging that the shot is safe, effective and critical for long-term protection.

A Narrow Vote to Delay the Birth Dose for Some Newborns

Under the new recommendation, only babies born to mothers who test positive for hepatitis B-or whose status is unknown-would still receive the birth dose. For infants of mothers who test negative, the vaccine can be delayed until two months, effectively dismantling the universal birth-dose strategy that has been in place for about 30 years.

SHERIDAN, WYOMING - December 8, 2025 - As more practices adopt chairside 3D printing, many clinicians worry quietly about what it means for long-standing dental lab relationships-but rather than replacing labs, in-house production is reshaping them into higher-value, more strategic partnerships built around clearly defined roles and shared digital workflows.

From Full Lab Dependency to Hybrid Production

For years, the dominant model in restorative and appliance production has been full lab dependency: every crown, bridge, model, surgical guide, night guard or retainer went out the door to a third-party provider. In that setup, "Lab controls your timeline. Lab controls your cost per case. Lab capacity limits your capacity. Emergency cases wait on lab availability."

SHERIDAN, WYOMING - December 4, 2025 - Ubicquia has unveiled a coordinated next-generation smart streetlighting portfolio built around its new UbiCell® Micro controller, major enhancements to the UbiVu® infrastructure management platform and the launch of UbiScout™, an AI video accessory that turns existing streetlights into multi-purpose urban sensors for safety, mobility and energy efficiency.

Integrated portfolio targets utilities and cities under pressure to modernize

With grid operators and municipalities facing rising energy costs, decarbonization targets and aging infrastructure, Ubicquia's new offering is designed to make large-scale modernization of streetlighting networks faster and more manageable. The company positions the portfolio as a way to deliver asset intelligence, remote control and AI analytics without wholesale replacement of installed luminaires.

SHERIDAN, WYOMING - December 4, 2025 - Velvære, a 60-acre wellness-focused, ski-in/ski-out residential community in Deer Valley's new East Village, has secured a restructured $555 million construction revolver to complete its luxury estates, vertical residences and private amenities, underscoring continued investor appetite for high-end U.S. residential destination projects.

$555 million revolver anchors a $1 billion alpine masterplan

The new capital structure combines $197 million in fresh financing from Anchor Loans with existing commitments into a multi-product construction revolver. Arranged and advised by LFB Ventures, with equity backing from Toba Capital, the facility is designed to fund land development, amenity construction and vertical build-out across the project's diverse product mix.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics is expanding its Cell Line Development Center of Excellence through a new partnership with ATUM, integrating the Leap-In Transposase® expression platform to help biopharma developers move monoclonal antibodies and complex next-generation biologics into the clinic faster and more cost-effectively.

New options for faster, more flexible cell line development

As pressure grows to launch high-value biologics at lower cost, drug sponsors are looking for cell line development (CLD) solutions that combine speed, robustness and scalability. AGC Biologics' collaboration with ATUM adds a modern transposase-based expression platform to its CLD toolkit, creating a menu of fit-for-purpose options for standard monoclonals, multi-specific antibodies and other complex molecules.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics has signed a new manufacturing agreement with AAVantgarde Bio to produce dual-vector AAV gene therapies for Stargardt disease and retinitis pigmentosa, positioning its BravoAAV™ platform at the center of next-generation treatments for inherited retinal disorders with no approved therapies.

Dual-vector AAV platform targets previously "untreatable" retinal genes

Under the deal, AGC Biologics will provide GMP manufacturing for AAVantgarde's two clinical-stage candidates: AAVB-039 for Stargardt disease, the most common inherited form of macular degeneration in children and young adults, and AAVB-081 for retinitis pigmentosa caused by Usher syndrome type 1B. Both programs are in Phase 1/2 trials, with AAVB-039 being tested in the U.S., UK and Europe, and AAVB-081 representing the first-ever dual AAV gene therapy in an ocular indication.

SHERIDAN, WYOMING - December 2, 2025 - Heidelberger Druckmaschinen AG (HEIDELBERG) is restructuring its largest site in Wiesloch-Walldorf, appointing long-time manager Orhan Bekyigit as plant director alongside his existing role as site head, in a move designed to sharpen competitiveness, streamline operations and support growth in international markets.

Strategic realignment at Heidelberg's largest production hub

The Wiesloch-Walldorf campus, with around 3,800 employees, is HEIDELBERG's biggest location worldwide and a central pillar of its global manufacturing and technology network. The new setup brings plant management and central site functions under one leadership, with Bekyigit now responsible for both operational execution and cross-site coordination.

SHERIDAN, WYOMING - December 2, 2025 - More than 3,000 print service providers worldwide are now using the cloud-based HEIDELBERG Customer Portal as a digital control center for their end-to-end production, underscoring how system integration and workflow automation are becoming decisive competitive factors in the global print and packaging industry.

Cloud platform becomes a digital command center for print plants

Three years after launch, Heidelberger Druckmaschinen AG's (HEIDELBERG) customer portal is evolving into a central hub for managing production, service and commercial processes. Over 7,000 individual users are actively leveraging the platform to digitalize and automate their operations, with a clear focus on improving efficiency, transparency and sustainability.